The HER2-enriched subtype is characterized by the overexpression of the HER2 protein, but it typically lacks ER and PR expression. This subtype tends to grow and spread more aggressively than the luminal subtypes. Treatment often includes targeted therapies such as trastuzumab (Herceptin) that specifically target the HER2 protein.
